These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 6462982)

  • 1. Immobilization hypercalcaemia with severe bone mineral loss and hypogonadism.
    Need AG; Morris HA; Horowitz M; Nordin BE
    Postgrad Med J; 1984 Jun; 60(704):415-9. PubMed ID: 6462982
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immobilization-related hypercalcaemia--a possible novel mechanism and response to pamidronate.
    Gallacher SJ; Ralston SH; Dryburgh FJ; Logue FC; Allam BF; Boyce BF; Boyle IT
    Postgrad Med J; 1990 Nov; 66(781):918-22. PubMed ID: 2267202
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of the components of the hypercalcaemia in a 14-year-old boy following prolonged immobilisation.
    Dibble JB; Penney MD
    Acta Paediatr Scand; 1983 Mar; 72(2):207-10. PubMed ID: 6301206
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypercalcaemia in association with renal failure: the role of immobilisation.
    Prince RL; Eisman JA; Simpson RW
    Aust N Z J Med; 1983 Feb; 13(1):8-10. PubMed ID: 6576751
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanism of malignant hypercalcaemia in carcinoma of the breast.
    Percival RC; Yates AJ; Gray RE; Galloway J; Rogers K; Neal FE; Kanis JA
    Br Med J (Clin Res Ed); 1985 Sep; 291(6498):776-9. PubMed ID: 3929936
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biochemical parameters of bone turnover during ten days of bed rest and subsequent mobilization.
    van der Wiel HE; Lips P; Nauta J; Netelenbos JC; Hazenberg GJ
    Bone Miner; 1991 May; 13(2):123-9. PubMed ID: 2059676
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Familial benign hypercalcaemia. Study of a large family.
    Menko FH; Bijvoet OL; Fronen JL; Sandler LM; Adami S; O'Riordan JL; Schopman W; Heynen G
    Q J Med; 1983; 52(206):120-40. PubMed ID: 6310672
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of aminohydroxypropylidene diphosphonate on the bone metabolism of patients with parathyroid adenoma.
    Ishimura E; Miki T; Koyama H; Harada K; Nakatsuka K; Inaba M; Nishizawa Y; Morii H
    Horm Metab Res; 1993 Sep; 25(9):493-7. PubMed ID: 8225204
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relative contribution of humoral and metastatic factors to the pathogenesis of hypercalcaemia in malignancy.
    Ralston SH; Fogelman I; Gardiner MD; Boyle IT
    Br Med J (Clin Res Ed); 1984 May; 288(6428):1405-8. PubMed ID: 6426577
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immobilisation hypercalcemia.
    Evans RA; Bridgeman M; Hills E; Dunstan CR
    Miner Electrolyte Metab; 1984; 10(4):244-8. PubMed ID: 6087102
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Immobilisation hypercalcaemia. 1 case (author's transl)].
    Baglin A; Goupil A; Lortat-Jacob A; Arfi S; Gueris J; Milhaud G; Benoit J
    Nouv Presse Med; 1978 Feb; 7(6):453-5. PubMed ID: 634783
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of thyrotoxicosis and its treatment on mineral and bone metabolism.
    Lalau JD; Sebert JL; Marie A; Fournier A; Quichaud J
    J Endocrinol Invest; 1986 Dec; 9(6):491-6. PubMed ID: 3571853
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evolution of renal osteodystrophy: correlation of bone histomorphometry and serum mineral and immunoreactive parathyroid hormone values before and after treatment with calcium carbonate or 25-hydroxycholecalciferol.
    Bordier PJ; Marie PJ; Arnaud CD
    Kidney Int Suppl; 1975 Jan; (2):102-12. PubMed ID: 1057669
    [No Abstract]   [Full Text] [Related]  

  • 15. Relative importance of renal failure and increased bone resorption in the hypercalcaemia of myelomatosis.
    Heyburn PJ; Child JA; Peacock M
    J Clin Pathol; 1981 Jan; 34(1):54-7. PubMed ID: 6450779
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bone resorption and renal calcium reabsorption in renal cell carcinoma-bearing mice: the effects of bisphosphonate.
    Weissglas M; Löwik C; Schamhart D; Theuns H; Kurth KH; Papapoulos S
    BJU Int; 2007 Jun; 99(6):1530-3. PubMed ID: 17428243
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of cancer associated hypercalcaemia with combined aminohydroxypropylidene diphosphonate and calcitonin.
    Ralston SH; Alzaid AA; Gardner MD; Boyle IT
    Br Med J (Clin Res Ed); 1986 Jun; 292(6535):1549-50. PubMed ID: 3087513
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mineral and bone metabolism in thyroid disease: a review.
    Auwerx J; Bouillon R
    Q J Med; 1986 Aug; 60(232):737-52. PubMed ID: 3774957
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 1 alpha-hydroxy vitamin D3 treatment of non-dialyzed patients with chronic renal failure. Effects on bone, mineral metabolism and kidney function.
    Nielsen HE; Rømer FK; Melsen F; Christensen MS; Hansen HE
    Clin Nephrol; 1980 Mar; 13(3):103-8. PubMed ID: 7379358
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Severe immobilization hypercalcemia, renal insufficiency, and calcification.
    Conley SB; Shackelford GD; Robson AM
    Pediatrics; 1979 Jan; 63(1):142-5. PubMed ID: 440790
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.